This search combines search strings from the content search (i.e. "Full Text", "Author", "Title", "Abstract", or "Keywords") with "Article Type" and "Publication Date Range" using the AND operator.
Beilstein J. Nanotechnol. 2019, 10, 2062–2072, doi:10.3762/bjnano.10.201
Figure 1: Resulting particle diameters and loading efficiencies for different nanoparticle formulations using...
Figure 2: SEM images of nanoparticles using emulsion diffusion (ED) or solvent displacement (SD) preparation ...
Figure 3: Doxorubicin (Dox) release profiles over 24 h for all nanoparticle systems using (A) emulsion diffus...
Figure 4: Doxorubicin (Dox) drug load and loading efficiency for PLGA nanoparticles (NPs) prepared using a PV...
Figure 5: (A) Drug load and loading efficiencies as well as (B) particle diameter and PDI for different amoun...
Figure 6: Release profiles of doxorubicin from PLGA nanoparticles prepared using an unmodified PVA solution a...
Figure 7: Doxorubicin concentrations that reduce neuroblastoma cell viability by 50% (IC50) when administered...
Figure 8: Doxorubicin concentrations that reduce UKF-NB-3rVCR1 viability by 50% (IC50) in the absence or pres...
Beilstein J. Nanotechnol. 2019, 10, 1707–1715, doi:10.3762/bjnano.10.166
Figure 1: SEM confirmed the spherical shape and narrow size distribution of doxorubicin-loaded HSA (100%) nan...
Figure 2: Doxorubicin sensitivity of UKF-NB-3, its doxorubicin-adapted sub-line UKF-NB-3rDOX20 and its vincri...
Figure 3: Effects of doxorubicin (Dox) applied as a solution or incorporated into human serum albumin (HSA) n...
Figure 4: Fold sensitisation to doxorubicin by doxorubicin-bound nanoparticles (NPs). Values are expressed as...
Figure 5: Doxorubicin (Dox) concentrations that reduce neuroblastoma cell viability by 50% (IC50) in the pres...